Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

8.40
-0.5400-6.04%
Post-market: 8.500.1000+1.19%19:16 EDT
Volume:1.39M
Turnover:12.03M
Market Cap:262.84M
PE:-2.95
High:9.25
Open:8.90
Low:8.40
Close:8.94
52wk High:50.40
52wk Low:8.40
Shares:31.29M
Float Shares:15.69M
Volume Ratio:0.67
T/O Rate:8.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8500
EPS(LYR):-2.8503
ROE:-33.63%
ROA:-21.86%
PB:0.92
PE(LYR):-2.95

Loading ...

D. Western Therapeutics Completes Global Phase III Follow-Up for Fuchs Drug K-321

TIPRANKS
·
Mar 19

Press Release: Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

Dow Jones
·
Mar 19

Neurizon Therapeutics Seeks ASX Quotation for 9.5 Million New Shares

TIPRANKS
·
Mar 19

Trevi Therapeutics Maps Phase III Path and Runway

TIPRANKS
·
Mar 19

Chimeric Therapeutics to Consolidate Shares and Equity Securities

TIPRANKS
·
Mar 19

Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)

TIPRANKS
·
Mar 19

Press Release: Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Dow Jones
·
Mar 19

Serina Therapeutics names Greg Bailey co-chairman

TIPRANKS
·
Mar 19

Stoke Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Mar 19

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

GlobeNewswire
·
Mar 19

These Analysts Revise Their Forecasts On Trevi Therapeutics Following Q4 Earnings

Benzinga_recent_news
·
Mar 19

Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm

TIPRANKS
·
Mar 19

Trevi Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Mar 18

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

GlobeNewswire
·
Mar 18

Stoke Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
Mar 18

Ovid Therapeutics Raises Capital to Expand Epilepsy Pipeline

TIPRANKS
·
Mar 18

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire
·
Mar 18

Trevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley

TIPRANKS
·
Mar 18

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

GlobeNewswire
·
Mar 18

Bicycle Therapeutics price target lowered to $36 from $44 at Oppenheimer

TIPRANKS
·
Mar 18